Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Published study of protein-based bladder cancer test shows 99% of malignancies found
February 14th, 2006
A simple point-of-care urine test, the NMP22 BladderChek Test, was found to significantly increase the detection of recurrent bladder cancer, finding 99% of the malignancies when used with cystoscopy, according to a report in the Journal of the American Medical Association (JAMA). The NMP22 BladderChek Test was developed and commercialized by Matritech (MZT), a developer of protein-based diagnostic products for the early detection of cancer. It is the only noninvasive point-of-care assay approved by the U.S. Food and Drug Administration (FDA) as an aid in both the initial diagnosis and monitoring of bladder cancer. Using only four drops of urine, the test detects...
Source: Cancer Weekly (2006-02-14)
|
